Francesca Palandri/LinkedIn
Aug 17, 2026, 16:22
Francesca Palandri: Why Is Ruxolitinib Response So Heterogeneous in Myelofibrosis?
Francesca Palandri, Hematologist at IRCCS Sant’Orsola Polyclinic – Bologna University Hospital, shared on LinkedIn about a recent article she and Filippo Branzanti co-authored, published in Clinical Lymphoma Myeloma and Leukemia, adding:
”Why is ruxolitinib response so heterogeneous in myelofibrosis?
Our SOHO State of the Art review covers:
- Cytopenic vs. proliferative phenotype
- Dose intensity (the 1 modifiable factor)
- HMR mutations, RAS/CBL, cytogenetics
- Dynamic models RR6, iRR6, STR-PM
Moving from static baseline prognostication to response-driven precision medicine.”
Title: SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis
Authors: Francesca Palandri, Filippo Branzanti

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 14, 2026, 16:35Sultan Aydın Aslantaş: A Rare Coexistence of LAHPS and Bloom Syndrome in a Child
-
Nov 14, 2026, 16:27Nicolas Moniotte: Dual-Platform Gene Editing for Haemophilia A
-
Nov 14, 2026, 15:30Patient Selection for Gene Therapy in Transfusion-Dependent β-Thalassemia – EHA
-
Nov 14, 2026, 15:07Vaidehi Prasanth: Patient Blood Management in Hematological Patients A New Book Chapter
-
Nov 14, 2026, 15:00Ram Mohan Jaiswal: International Collaboration in Transfusion Medicine Through the Trans Med Africa Consortium
-
Nov 14, 2026, 14:48Jamie Sin Ying Ho: Stopping Anticoagulation After AF Ablation and Rhythm Control
-
Nov 14, 2026, 14:29Satya Prakash: Cell-Free Hemoglobin-Based Oxygen Carriers and Their Clinical Development
-
Nov 14, 2026, 14:24Adela Castro: Distinguishing Antiphospholipid Antibodies From APS in Pregnancy
-
Nov 14, 2026, 14:20Uzima Chirwa: Rethinking Comprehensive Care for Bleeding Disorders in Africa